1383 related articles for article (PubMed ID: 2825708)
1. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
3. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
4. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
Delpy E; Coste H; Gouville AC
Br J Pharmacol; 1996 Oct; 119(3):471-8. PubMed ID: 8894166
[TBL] [Abstract][Full Text] [Related]
5. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
6. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
Komas N; Lugnier C; Stoclet JC
Br J Pharmacol; 1991 Oct; 104(2):495-503. PubMed ID: 1665741
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
8. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
9. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
10. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
11. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro.
Truss MC; Uckert S; Stief CG; Kuczyk M; Schulz-Knappe P; Forssmann WG; Jonas U
Neurourol Urodyn; 1996; 15(1):59-70. PubMed ID: 8696357
[TBL] [Abstract][Full Text] [Related]
12. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
14. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.
Yu SM; Cheng ZJ; Kuo SC
Eur J Pharmacol; 1995 Jun; 280(1):69-77. PubMed ID: 7498256
[TBL] [Abstract][Full Text] [Related]
15. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; CairrĂ£o E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
Delpy E; le Monnier de Gouville AC
Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
18. [Effect of several hormones on cyclic 3',5'-nucleotide phosphodiesterase in rat kidneys].
Iwase K
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1678-91. PubMed ID: 6319206
[TBL] [Abstract][Full Text] [Related]
19. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]